Associated Papers
Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider.
Roncato R et al.
British Journal of Clinical Pharmacology, 2026
Do Socio-Economic Determinants Influence DPYD Testing? A Real-World Study of 1478 Cancer Patients Receiving Fluoropyrimidine Chemotherapy.
Baraka B et al.
Medical Sciences (basel, Switzerland), 2026
Optimizing fluoropyrimidine therapy: Real-world impact of DPYD genotype-based dosing on severe toxicity rates.
van Kan AHE et al.
British Journal of Clinical Pharmacology, 2026
Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.
Tremmel R et al.
Clinical Pharmacology and Therapeutics, 2026
Development of a comprehensive cardiovascular disease genetic risk assessment test.
Amendola LM et al.
Genetics in Medicine Open, 2026
A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.
Boige V et al.
Journal of the National Cancer Institute, 2025
Potential clinical relevance of rare dihydropyrimidine dehydrogenase genetic variants identified using whole-exome NextGen sequencing in cancer patients with severe fluoropyrimidine toxicity.
Cui E et al.
Cancer Chemotherapy and Pharmacology, 2025
Clinical implementation and outcome evaluation of dihydropyrimidine dehydrogenase (DPYD) pharmacogenomic testing for fluoropyrimidine dosing in a Canadian Provincial Healthcare center.
Wu F et al.
Clinical Biochemistry, 2025
Severe toxicity following genotype-guided reduced 5-FU dose in a heterozygous DPYD c.2846A>T carrier with stage III anal carcinoma: A case report.
Norris ML et al.
Cancer Chemotherapy and Pharmacology, 2025
Real-world study on fluoropyrimidine-related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype-guided dosing.
Peeters SLJ et al.
International Journal of Cancer, 2025
Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity - A secondary analysis of the PREPARE trial.
De Mattia E et al.
Oncogene, 2025
Association between miRNA expression profiles and polymorphisms of dihydropyrimidine dehydrogenase drug-metabolizing gene in patients with colorectal cancer receiving 5-fluorouracil.
Phannasil P et al.
Biomedical Reports, 2025
Risk vs Prevalence: Weighing Routine DPYD Variant Testing Prior to Fluoropyrimidine-Based Chemotherapy.
Larkey NE et al.
Clinical Chemistry, 2025
Opportunities and Challenges of Population Pharmacogenomics.
Zhou Y et al.
Annals of Human Genetics, 2025
Suspected capecitabine-induced fatal toxicity in the context of a new DPYD variant.
Thet PN et al.
Bmj Case Reports, 2025
A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of DPYD: A Call to Revise European Pharmacogenetic Guidelines.
Gil-Rodriguez A et al.
International Journal of Molecular Sciences, 2025
Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects.
Bernsen EC et al.
Clinical Pharmacology and Therapeutics, 2025
Unrecognized mutations in DPYD* 2 A wild-type rectal cancer patients receiving postoperative 5-FU-based chemotherapy - do they have a clinical impact?
Liersch P et al.
Cancer Chemotherapy and Pharmacology, 2025
Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trial.
Glewis S et al.
British Journal of Clinical Pharmacology, 2025
The Path to Clinical Implementation of <italic>DPYD</italic> Pharmacogenetic Testing: Long-Term Experience from an External Quality Assessment Provider and a University Testing Center.
Hedtke M et al.
Oncology Research and Treatment, 2025
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.
Knikman JE et al.
European Journal of Cancer (oxford, England : 1990), 2025
Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine.
Díaz-Villamarín X et al.
Journal of Personalized Medicine, 2025
Impact of Upfront DPYD Genotyping on Fluoropyrimidine Adjuvant Therapy in Colorectal Cancer: A Real-World Data.
Saarenheimo J et al.
Clinical Colorectal Cancer, 2025
Precision Treatment of Patients With GI Cancer Using Pre-emptive DPYD Genotyping/Phenotyping Plus Pharmacokinetic-Guided Dosing of 5-Fluorouracil.
Fiebrich-Westra HB et al.
Jco Precision Oncology, 2025
DPYD Genotyping, Fluoropyrimidine Dosage and Toxicity: An Umbrella Review of Systematic Reviews.
Otero-Torres S et al.
Pharmaceuticals (basel, Switzerland), 2025
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice.
Ho TT et al.
Clinical Pharmacology and Therapeutics, 2025
Implementing DPYD genotyping to predict chemotherapy toxicity in Australia: a feasibility study.
White C et al.
Internal Medicine Journal, 2025
Development of an Ancestrally Inclusive Preemptive Pharmacogenetic Testing Panel.
Lteif C et al.
Clinical and Translational Science, 2025
Application of dihydropyrimidine dehydrogenase deficiency testing for the prevention of fluoropyrimidine toxicity: a real-world experience in a Southern Italy cancer center.
Bianchino G et al.
Journal of Chemotherapy (florence, Italy), 2025
Differences in DPYD Population Frequencies Observed in Galicians Compared to Europeans and Spanish from PhotoDPYD Study.
Gil-Rodriguez A et al.
Pharmaceuticals (basel, Switzerland), 2025
Pharmacogenetic Testing in Admixed Populations: Frequency of the Association for Molecular Pathology Pharmacogenomics Working Group Tier 1 Variant Alleles in Brazilians.
Suarez-Kurtz G
The Journal of Molecular Diagnostics : Jmd, 2025
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature.
Liguori C et al.
Cancer Chemotherapy and Pharmacology, 2025
Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical Implications.
Sánchez-Bayona R et al.
Cancers, 2025
Genetic and Functional Characterization of DPYD Exon 4 Deletion Common in the Finnish Population.
Kiiski JI et al.
Basic & Clinical Pharmacology & Toxicology, 2025
Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice.
Leong IUS et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2025
Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial).
Hanrath MA et al.
Cancer Chemotherapy and Pharmacology, 2025
Pharmacogenomics: DPYD and Prevention of Toxicity.
Keen J et al.
Clinical Oncology (royal College of Radiologists (great Britain)), 2025
Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution.
D'Amato M et al.
World Journal of Gastrointestinal Oncology, 2025
Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.
Litonius K et al.
Clinical Pharmacology and Therapeutics, 2025
Comprehensive pharmacogenomics profiling of the Serbian population.
Jelovac M et al.
Frontiers in Pharmacology, 2025
Balance of care activity after EMA recommendation for DPYD gene testing in Galicia.
Gil-Rodríguez A et al.
Frontiers in Pharmacology, 2025
Unveiling the heritability of selected unexplored pharmacogenetic markers in the Saudi population.
Alshabeeb MA et al.
Frontiers in Pharmacology, 2025
Clinical impact of pharmacogenomics in pediatric care: insights extracted from clinical exome sequencing.
Maggo S et al.
Frontiers in Genetics, 2025